Evidence map›Paper›PMID 31801187›Full record

ArticleCells2019

Dibutyltin(IV) and Tributyltin(IV) Derivatives of

Francesca Costantini, Fabiana Di Leo, Caterina Di Sano, Tiziana Fiore, Claudia Pellerito, Giovanna Barbieri

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The Hydroxytyrosol Induces the Death for Apoptosis of Human Melanoma Cells.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Francesca CostantiniIstituto per la Ricerca e l'Innovazione Biomedica (IRIB), Consiglio Nazionale delle Ricerche (CNR), 90146 Palermo, Italy.
Fabiana Di LeoIstituto per la Ricerca e l'Innovazione Biomedica (IRIB), Consiglio Nazionale delle Ricerche (CNR), 90146 Palermo, Italy.
Caterina Di SanoIstituto per la Ricerca e l'Innovazione Biomedica (IRIB), Consiglio Nazionale delle Ricerche (CNR), 90146 Palermo, Italy.
Tiziana FioreDipartimento di Fisica e Chimica, Università degli Studi di Palermo, 90128 Palermo, Italy.ORCID 0000-0002-0604-2696
Claudia PelleritoDipartimento di Fisica e Chimica, Università degli Studi di Palermo, 90128 Palermo, Italy.
Giovanna BarbieriIstituto per la Ricerca e l'Innovazione Biomedica (IRIB), Consiglio Nazionale delle Ricerche (CNR), 90146 Palermo, Italy.ORCID 0000-0002-5895-1795
Institute for Biomedical Research and Innovation · ITConsorzio Interuniversitario Reattività Chimica e Catalisi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is the most aggressive and deadly form of skin cancer, which is largely due to its propensity to metastasize. Therefore, with the aim to inhibit the growth and the metastatic dissemination of melanoma cells and to provide a novel treatment option, we studied the effects of the melanoma treatment with two organotin(IV) complexes of the

Indexed as

Antineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationDose-Response Relationship, DrugFocal Adhesion Kinase 1HumansMelanomaMolecular StructurePorphyrinsSignal TransductionAntineoplastic AgentsFocal Adhesion Kinase 1PorphyrinsPTK2 protein, humantetraphenylporphine sulfonateBRAFcell cyclecellular growthmelanomamigrationorganotin(IV)

Identifiers

PMID31801187
PMCPMC6952936
OpenAlexW2990135442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.